MedTrace Logo

Antibiotic Prophylaxis for HDR Brachytherapy in the Treatment of Prostate Cancer

NCT03862170 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2025-02-12

No results posted yet for this study

Summary

Phase III study that aims to evaluate the necessity of prophylactic antibiotics use after HDR brachytherapy in the treatment of prostate adenocarcinomas.

Conditions

Interventions

DRUG

Ciprofloxacin

Ciprofloxacin 400 mg IV 120mn before HDR brachytherapy

DRUG

Cefazolin

Sponsors & Collaborators

  • CR-CSSS Champlain-Charles-Le Moyne

    lead OTHER

Principal Investigators

  • Marjory Jolicoeur, MD,MSc · CSSS Champlain-Charles-Le Moyne

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-10
Primary Completion
2020-02-29
Completion
2023-02-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03862170 on ClinicalTrials.gov